Fate Therapeutics, Inc. $FATE Stock Holdings Lessened by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio trimmed its stake in Fate Therapeutics, Inc. (NASDAQ:FATE) by 30.1% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 113,655 shares of the biopharmaceutical company’s stock after selling 49,000 shares during the quarter. Public Employees Retirement System of Ohio owned 0.10% of Fate Therapeutics worth $127,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also made changes to their positions in FATE. CWM LLC lifted its position in shares of Fate Therapeutics by 899.6% in the first quarter. CWM LLC now owns 41,435 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 37,290 shares in the last quarter. Caption Management LLC acquired a new position in Fate Therapeutics in the first quarter worth approximately $45,000. Jane Street Group LLC raised its position in Fate Therapeutics by 106.9% during the first quarter. Jane Street Group LLC now owns 63,691 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 32,911 shares in the last quarter. Squarepoint Ops LLC raised its position in Fate Therapeutics by 154.2% during the fourth quarter. Squarepoint Ops LLC now owns 34,295 shares of the biopharmaceutical company’s stock valued at $57,000 after acquiring an additional 20,805 shares in the last quarter. Finally, Comerica Bank raised its position in Fate Therapeutics by 55,698.6% during the first quarter. Comerica Bank now owns 82,024 shares of the biopharmaceutical company’s stock valued at $65,000 after acquiring an additional 81,877 shares in the last quarter. 97.54% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Fate Therapeutics in a research report on Thursday, June 12th. Wall Street Zen raised shares of Fate Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, August 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Fate Therapeutics in a research report on Saturday, September 27th. Finally, Wells Fargo & Company cut their price objective on shares of Fate Therapeutics from $4.00 to $2.50 and set an “equal weight” rating on the stock in a research report on Wednesday, August 13th. One investment analyst has rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $3.30.

Fate Therapeutics Trading Down 1.4%

Shares of Fate Therapeutics stock opened at $1.39 on Wednesday. The company’s fifty day simple moving average is $1.06 and its 200-day simple moving average is $1.11. The company has a market cap of $160.31 million, a price-to-earnings ratio of -0.96 and a beta of 2.34. Fate Therapeutics, Inc. has a 1 year low of $0.66 and a 1 year high of $3.50.

Fate Therapeutics (NASDAQ:FATE) last announced its quarterly earnings data on Tuesday, August 12th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.06. The business had revenue of $1.91 million for the quarter, compared to the consensus estimate of $1.16 million. Fate Therapeutics had a negative net margin of 2,025.05% and a negative return on equity of 50.95%. As a group, research analysts forecast that Fate Therapeutics, Inc. will post -1.63 earnings per share for the current fiscal year.

About Fate Therapeutics

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.